Search clinical trials for: PYY1-36 sitagliptin

Total 1011 results

AstraZeneca

Completed

Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants

Type 2 Diabetes Mellitus

United States
Boehringer Ingelheim

Completed

Bioavailability of BI 1356 After Single Oral Administration Given as Different Tablet Formulation in Healthy Male Volunteers

Healthy
Lexicon Pharmaceuticals

Completed

A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics

Type 2 Diabetes Mellitus

United States
Boehringer Ingelheim

Terminated

Real-world Study Comparing the Adherence and Effectiveness of Linagliptin vs. Acarbose

Diabetes Mellitus, Type 2

China
Zilin Sun

Completed

Combining Saxagliptin and Acarbose to Improve Postprandial Glycaemia in Type 2 Diabetes

Type 2 Diabetes

China
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 1356 BS in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 10773 and Linagliptin in Healthy Male Volunteers

Healthy
Memorial Sloan Kettering Cancer Center
University of Texas Southwestern Medical Center; Wake Forest University

Active, not recruiting

Investigating Mechanisms to Explain Age Associated Differences in Quality of Life Among Breast Cancer Patients

Breast Cancer

United States
Postgraduate Institute of Medical Education and...

Unknown

Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus | Insulin Sensitivity/Resistance

India
The University of Texas Health Science Center,...
The Center for Clinical and Translational Sciences (CCTS) Clinical Research...

Completed

Effects of Antidiabetic Medications on the Postprandial State in Prediabetes

Obesity | Prediabetes

United States
Yanbing Li

Unknown

A Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin Therapy

Type 2 Diabetes Mellitus | Peritoneal Dialysis

China
AstraZeneca

Completed

24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy (SMART)

Type 2 Diabetes Mellitus

China
AstraZeneca

Completed

A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone

Diabetes Mellitus, Type 2

United States, Argentina, Canada, Puerto Rico, Mexico, Philippines, India, Peru
Radboud University Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development; Sint...

Completed

Persistent Lyme Empiric Antibiotic Study Europe (PLEASE)

Lyme Disease | Borrelia Infection

Netherlands
Brunel University
University of Sao Paulo

Unknown

Dysfunctional Breathing: Characterisation and Assessment

Breathlessness | Hyperventilation Syndrome | Respiration Disorder | Breath Shortness

United Kingdom
RWTH Aachen University

Terminated

Diastolic Dysfunction in Patients With Type 2 Diabetes Mellitus (Diast Dysfkt)

Diabetes Mellitus Type 2 (T2DM) | Left Ventricular Diastolic Dysfunction

Germany
Beth Israel Deaconess Medical Center

Completed

The Effect of Linagliptin on Mitochondrial and Endothelial Function

Type II Diabetes Mellitus

United States
Fifth Affiliated Hospital, Sun Yat-Sen University

Unknown

Safety and Efficacy of Acarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus
Boehringer Ingelheim

Completed

Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

Diabetes Mellitus, Type 2

United States, Canada, Thailand, Korea, Republic of, United Kingdom, China, Germany, Israel, Mexico, Argentina, Brazil, Colombia, Puerto Rico, Russian Federation
AstraZeneca

Completed

Bioequivalence Study Coadministered to Healthy Subjects in the Fasted State

Type 2 Diabetes Mellitus
Changchun GeneScience Pharmaceutical Co., Ltd.
Sixth Affiliated Hospital, Sun Yat-sen University

Recruiting

To Investigate Efficacy and Safety of a Single Injection of GenSci094 for Ovarian Stimulation Using Daily Recombinant FSH as Reference (ANGAS)

Infertility

China
Janssen Scientific Affairs, LLC

Completed

A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder

Schizoaffective Disorder

United States, Ukraine, Bulgaria, India, Malaysia, Romania, South Africa, Philippines
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356 BS Administered to Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design

Diabetes Mellitus, Type 2

Canada, Croatia, Estonia, France, Germany, India, Lithuania, Mexico, Netherlands, Romania, Russian Federation, Sweden, Tunisia, Ukraine
Johns Hopkins University
National Institute on Drug Abuse (NIDA)

Completed

Effect of Zonisamide on Cocaine Reinforcement, Craving, and Relapse

Cocaine Dependence

United States
AstraZeneca

Completed

Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP) (HARRP)

Type 2 Diabetes Mellitus

Sweden
AstraZeneca

Completed

A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Diabetes

United States, United Kingdom, Germany, Hungary, Mexico, Poland, Russian Federation, Romania, Czechia, Sweden
Boehringer Ingelheim

Completed

BI 1356 BS in Japanese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2
AstraZeneca

Completed

Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Type 2 Diabetes

United States, Puerto Rico, Mexico, Russian Federation, Romania, Poland, Czech Republic, United Kingdom
The University of Texas Health Science Center at...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); A... and other collaborators

Recruiting

Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)

Diabetes Mellitus, Type 2 | Impaired Glucose Tolerance (IGT) | Impaired Fasting Glucose (IFG)

United States
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2
Boehringer Ingelheim

Completed

Investigation of the Metabolism and Pharmacokinetics of 10 mg [14C] BI 1356 Administered Orally Compared to 5 mg [14C] BI 1356 Administered Intravenously in Healthy Male Volunteers

Healthy
The Affiliated Nanjing Drum Tower Hospital of Nanjing...
Nanjing First Hospital, Nanjing Medical University; Wuxi People's Hospital; Changzhou... and other collaborators

Recruiting

Effects of Liraglutide, Empagliflozin and Linagliptin on the Cognitive Function in T2DM Patients With Mild Cognitive Impairment: a Multicenter, Randomized, Parallel Controlled Clinical Trial (LIGHT-MCI)

Type 2 Diabetes Mellitus | Mild Cognitive Impairment

China
Boehringer Ingelheim

Completed

Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

United States, Australia, Canada, Czech Republic, Russian Federation, Ukraine
The Affiliated Nanjing Drum Tower Hospital of Nanjing...
The First Affiliated Hospital with Nanjing Medical University; The First Affiliated... and other collaborators

Completed

Efficacy and Safety of Saxagliptin VS. Glimepiride in Chinese T2DM Patients Controlled Inadequately With Metformin (SPECIFY)

Type 2 Diabetes

China
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Argentina, Australia, Canada, El Salvador, Germany, Italy, Portugal, Russian Federation, Spain, Ukraine
Boehringer Ingelheim

Completed

The Effect of Multiple Oral Doses of BI 1356 BS on Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of Simvastatin and on the Pharmacokinetics of Its Metabolite Simvastatin Acid in Healthy Male Volunteers

Healthy
RWTH Aachen University

Terminated

Effect of Linagliptin on Vascular Inflammation in Patients With Type 2 Diabetes Mellitus (Lina-Plaque)

Diabetes Mellitus Type 2 (T2DM) | Vascular Inflammation | Plaque Morphology

Germany, Netherlands
Merck Sharp & Dohme LLC

Completed

MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036)

Type 2 Diabetes Mellitus
Kaplan Medical Center

Unknown

Nasal Ketamine for Minor Procedures in Children

Pain
Ministry of Health, Jamaica
University Hospital of the West Indies

Completed

Penile Fracture: A Comparison of Erectile Function After Immediate Repair Versus Delayed Repair

Erectile Dysfunction

Jamaica
Yale University
National Institute on Drug Abuse (NIDA)

Completed

Investigation of Cocaine Addiction Using mGluR5 PET and fMRI

Cocaine Dependence

United States
University of Nebraska

Completed

Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery

Hypotension on Induction

United States
Boehringer Ingelheim

Completed

Bioavailability of BI 1356 After Co-administration With Ritonavir Compared to the Bioavailability of BI 1356 Alone in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Bulgaria, Denmark, France, Germany, Hong Kong, Hungary, India, Ireland, Italy, Netherlands, Norway, Poland, South Africa, Sweden, United Kingdom
Boehringer Ingelheim

Completed

Japanese P III vs Voglibose and Placebo

Diabetes Mellitus, Type 2

Japan
Erasme University Hospital

Terminated

Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.

Type 2 Diabetes | Pancreas | Incretinomimetics

Belgium
National Institutes of Health Clinical Center (CC)

Completed

Drug Interaction Study Between Inhaled Beclomethasone and Protease Inhibitors in Healthy Volunteers

Asthma | HIV

United States
Boehringer Ingelheim

Completed

Effect of BI 1356 as Single Dose on the QT Interval in Healthy Female and Male Subjects

Healthy
Boehringer Ingelheim

Completed

Relative Bioavailability of 1 mg and 10 mg BI 1356 BS as Powder in the Bottle (PIB) to 1 mg and 10 mg BI 1356 BS as Tablets as Single Oral Administration in Healthy Male Volunteers Including the Influence of Food on the Bioavailability of 10 mg BI 1356 BS

Healthy

3

Subscribe